NCT04083235 2026-03-09
NAPOLI 3
Ipsen
Phase 3 Completed
Clinical Trials
79 trialsNCT03976362 2026-02-25
KEYLYNK-008
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02705196 2026-02-24
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
Lokon Pharma AB
Phase 1/2 Completed
NCT05226598 2026-02-05
MK-7684A-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03456063 2026-01-22
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
Hoffmann-La Roche
Phase 3 Completed
NCT04148911 2025-12-26
EL1SSAR
Hoffmann-La Roche
Phase 3 Completed
NCT03193190 2025-11-21
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT03184870 2025-10-09
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03776812 2025-10-07
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Corcept Therapeutics
Phase 2 Completed
NCT04306900 2025-07-29
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
Phase 1 Completed
NCT05673811 2025-04-16
VIRAGE
Theriva Biologics SL
Phase 2 Completed
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT06538207 2025-02-06
An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer
Ono Pharmaceutical Co. Ltd
Phase 1 Completed
NCT05031494 2025-01-06
A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers
Eucure (Beijing) Biopharma Co., Ltd
Phase 2 Completed
NCT02819518 2024-11-27
KEYNOTE-355
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01010945 2024-11-21
Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
Astellas Pharma Inc
Phase 1 Completed
NCT05390710 2024-10-10
PhI to Solid Tumors and PhII to Locally Advanced or mTNBC
Laekna Limited
Phase 1 Completed
NCT02775435 2024-10-08
KEYNOTE-407
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03517176 2024-08-28
CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
Lisata Therapeutics, Inc.
Phase 1 Completed
NCT03267316 2024-08-22
CANFOUR
Cantargia AB
Phase 1/2 Completed
NCT03421353 2024-08-21
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
AstraZeneca
Phase 1 Completed
NCT03336216 2024-07-23
A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT04742959 2024-04-26
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
Phase 1/2 Completed
NCT02231723 2023-11-18
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT02993731 2023-11-15
CanStem111P
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT04299880 2023-11-08
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT04247126 2023-10-27
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
Syros Pharmaceuticals
Phase 1 Completed
NCT03197935 2023-10-26
IMpassion031
Hoffmann-La Roche
Phase 3 Completed
NCT03611556 2023-10-03
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
MedImmune LLC
Phase 1/2 Completed
NCT03840915 2023-08-21
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
EMD Serono
Phase 1/2 Completed
NCT01964430 2023-06-28
apact
Celgene
Phase 3 Completed
NCT03872791 2023-06-08
A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2 Completed
NCT02915744 2023-04-14
ATTAIN
Nektar Therapeutics
Phase 3 Completed
NCT04584112 2023-03-15
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT02210559 2023-03-02
A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer
Kyntra Bio
Phase 1/2 Completed
NCT04196283 2023-02-27
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
AbbVie
Phase 1 Completed
NCT01647828 2023-02-15
ALPINE
Mereo BioPharma
Phase 1/2 Completed
NCT04481009 2022-12-12
A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
Phase 1/2 Completed
NCT02762981 2022-12-06
Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
Corcept Therapeutics
Phase 1/2 Completed
NCT04132817 2022-12-02
A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread
Bristol-Myers Squibb
Phase 1 Completed
NCT02857270 2022-11-22
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT03665441 2022-10-18
Trybeca-1
ERYtech Pharma
Phase 3 Completed
NCT03085914 2022-09-23
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Incyte Corporation
Phase 1/2 Completed
NCT02425891 2022-07-19
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
Hoffmann-La Roche
Phase 3 Completed
NCT03086369 2022-06-28
A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT03412799 2022-05-25
Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
Panbela Therapeutics, Inc.
Phase 1 Completed
NCT02367794 2022-03-21
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
Hoffmann-La Roche
Phase 3 Completed
NCT02799862 2021-10-06
NEPTUN
iOMEDICO AG
Completed
NCT02367781 2021-08-09
IMpower130
Hoffmann-La Roche
Phase 3 Completed
NCT02715531 2021-07-09
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Hoffmann-La Roche
Phase 1 Completed